FOLLOW THE DRUG MONEY: America's Broken Healthcare System

By BurAnd @ Shutterstock.com

You really can’t make this stuff up. Do we need yet another example of how our healthcare system is broken? Just follow the money. Not that I’m buying into this cure-all pill. Alex Berenson writes on his Substack:

Life Comes at You Fast. Slow It Down with My Friday Email. It’s Free.

Yes, molnupiravir – a pill to treat Covid – seems to reduce hospitalizations and deaths, assuming Merck’s press release from last week holds up.

But it is yet another story of the US health care system and drug development gone awry.

A Miami hedge-fund manager and his wife – Wayne and Wendy Holman – are likely to make hundreds of millions of dollars, possibly billions, on it – and they took almost no risk. They basically got in the way of Merck licensing it from Emory University, where taxpayers had paid for its early development (this is how we make drugs in the United States, friends).

Added bonus: almost 20 years ago, Wendy Holman, who at the time had a different husband and a different last name, saw her name pop up in the same insider trading scandal that ensnared Martha Stewart. It too involved a drug company.

(Wendy Commins Blake aka Holman denied wrongdoing, was never charged, and eventually married Wayne Holman. A few years later the newlyweds found their way to Miami’s Star Island, where they bought a mansion for $28.8 million and the one next to it for $18 million. You read that right.)

The Washington Post had a long piece on the ugly little story of Ridgeback in June 2020. But now that Uncle Joe is president and not the Orange Man, the Post tries not to write anything that might reduce your confidence in Big, Medium, or Small Pharma (and by extension vaccines).

Here’s the lead of the Post piece:

“Ridgeback Biotherapeutics had no laboratories, no manufacturing facility of its own and a minimal track record when it struck a deal in March with Emory University to license an experimental coronavirus pill invented by university researchers with $16 million in grants from U.S. taxpayers.”

By May, Ridgeback had sold the rights to molnupiravir to Merck for “an undisclosed upfront payment, specified milestones and a share of the net proceeds of EIDD-2801 and related molecules, if approved.”

Neither Merck nor Ridgeback has ever disclosed how much Merck paid Ridgeback, nor the royalty rates on the drug. But Merck has said it plans to charge $700 for a course of molnupiravir in the United States and that it expects to produce 10 MILLION courses by year-end 2021, implying $7 billion in sales within months. (Forbes reports the actual cost of the drug is under $20 per course, based on what Indian manufacturers plan to charge.)

Merck has added about $20 billion in market capitalization since it announced the results.

But the real winners are the Holmans. Their royalty rate is based on “net profits,” per Merck’s 10-K – though Merck does not disclose how those will be calculated, or what the rate is. For simplicity’s sake, let’s assume $600 of the $700 Merck is charging will be net profit (this is probably low).

If the Holmans are receiving a 5 percent royalty, they will make $300 million from this year’s courses alone; 10 percent would net them $600 million; and 15 percent $900 million.

How much will they actually make?

Come on, Wayne and Wendy, share with the group!

It’s our money, after all. Or at least it was.

Action Line: When you invest with anyone who isn’t a fiduciary—the federal government for example, where you unwillingly invest with your tax dollars—you’ll find that you invest, and they win. Make sure whoever is helping you invest your money has a fiduciary duty to put your interests first, and will approach your interests as a “Prudent Man.” The government surely won’t do that, and neither will the Holmans of the world. If you want to learn more about fiduciary duty, I would love to talk with you.

Bio
Latest Posts

E.J. Smith - Your Survival Guy

E.J. Smith is Founder of YourSurvivalGuy.com, Managing Director at Richard C. Young & Co., Ltd., a Managing Editor of Richardcyoung.com, and Editor-in-Chief of Youngresearch.com. His focus at all times is on preparing clients and readers for “Times Like These.” E.J. graduated from Babson College in Wellesley, Massachusetts, with a B.S. in finance and investments. In 1995, E.J. began his investment career at Fidelity Investments in Boston before joining Richard C. Young & Co., Ltd. in 1998. E.J. has trained at Sig Sauer Academy in Epping, NH. His first drum set was a 5-piece Slingerland with Zildjians. He grew-up worshiping Neil Peart (RIP) of the band Rush, and loves the song Tom Sawyer—the name of his family’s boat, a Grady-White Canyon 306. He grew up in Mattapoisett, MA, an idyllic small town on the water near Cape Cod. He spends time in Newport, RI and Bartlett, NH—both as far away from Wall Street as one could mentally get. The Newport office is on a quiet, tree lined street not far from the harbor and the log cabin in Bartlett, NH, the “Live Free or Die” state, sits on the edge of the White Mountain National Forest. He enjoys spending time in Key West (RIP JB) and Paris. Please get in touch with E.J. at ejsmith@yoursurvivalguy.com To sign up for my free monthly Survive & Thrive letter, click here.